makers of semaglutide Apotex Gets Approval to Sell Generic in Canada | Chris Hannay posted on the topic Ozempic's weight-loss drug Wegovy available

These typically subside as dosing stabilizes

The introduction of a triple-agonist peptide threatens to replace current GLP-1 drugs as the dominant weight-loss therapy once the compound enters mainstream healthcare

PlexusDx clinicians monitor symptom patterns closely and can adjust dosing or compound strength to reduce intolerable reactions

Subscribers were up 41% in Q1 2025, to 1.7 million

Keywords: metabolic reprogramming, glucagon-like peptide-1 receptor agonists, heart failure, cardiovascular system, diabetes 1

The FDA position In January of a recent evaluation cycle, the FDA conducted a preliminary assessment of GLP-1 receptor agonists and psychiatric side effects